The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | Highlights on interesting data presented at COMy 2017
Meletios-Athanassios Dimopoulos, MD, from the Athens School of Medicine, Athens, Greece, discusses interesting data presented at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. At this meeting, speakers focused on controversial issues in the treatment of multiple myeloma (MM). Dr. Dimopoulous mentions some specific data presented: the role of consolidation after high-dose therapy, whether maintenance with lenalidomide be given to all patients, and what the duration of lenalidomide treatment should be for these patients. He further mentions some data presented regarding the activity of new agents for the treatment of MM such as venetoclax or selinexor. These are drugs that have a completely different mechanism of action, selinexor especially may have shown activity in patients who have failed treatment with not only proteasome inhibitors and immunomodulatory agents, but also with anti CD38 monoclonal antibodies.
